Alerts and enforcement
Compounding Form 483 Tracker
Facility; inspection; observations; response; later warning letter/classification; not-final-determination context.
A Form 483 lists observations made by an FDA investigator at the close of an inspection. It is not a final agency determination and must never be reported as one. Observations describe conditions the investigator judged may violate the Act. They are the investigator's findings, issued at the end of the inspection, and the firm has an opportunity to respond.
Key findings
- Observations describe conditions the investigator judged may violate the Act. They are the investigator's findings, issued at the end of the inspection, and the firm has an opportunity
- A 483 may be followed by no further action, by a warning letter, or by other enforcement. The outcome, not the observation, determines the firm's regulatory standing.
- Sector-wide, 53 of the 55 inspected 503B facilities had received a Form 483 as of July 2025, which means a 483 alone is weak signal without reading its content and outcome.
- This platform records observations separately from final actions, and will not present one as the other.
- Entity-specific compliance with this standard is not asserted on this page.
| Facility | Verification Pending |
|---|---|
| Inspection | Verification Pending |
| Observations | Verification Pending |
| Response | Verification Pending |
| Later warning letter/classification | Verification Pending |
| Not-final-determination context. | Verification Pending |
| Federal framework | License Verified FDA sources verified 2026-07-23 |
| Entity-specific data | Verification Pending |
What this standard actually requires
A Form 483 lists observations made by an FDA investigator at the close of an inspection. It is not a final agency determination and must never be reported as one.
Observations describe conditions the investigator judged may violate the Act. They are the investigator's findings, issued at the end of the inspection, and the firm has an opportunity to respond.
A 483 may be followed by no further action, by a warning letter, or by other enforcement. The outcome, not the observation, determines the firm's regulatory standing.
Sector-wide, 53 of the 55 inspected 503B facilities had received a Form 483 as of July 2025, which means a 483 alone is weak signal without reading its content and outcome.
This platform records observations separately from final actions, and will not present one as the other.
What is established about facility?
For compounding pharmacy Form 483, facility is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where facility has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about inspection?
For compounding pharmacy Form 483, inspection is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where inspection has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about observations?
For compounding pharmacy Form 483, observations is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where observations has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about response?
For compounding pharmacy Form 483, response is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where response has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about later warning letter/classification?
For compounding pharmacy Form 483, later warning letter/classification is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where later warning letter/classification has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What does this page establish?
It establishes the framework and the source map for compounding pharmacy Form 483, drawn from FDA primary sources verified on 2026-07-23. Framework facts — what the statute says, what registration means, which agency holds which record — are stable and checkable, and they are cited inline.
What it does not establish is any entity-specific fact. This platform separates those two categories deliberately, because they carry different verification burdens. A statutory definition can be cited once and relied on; a pharmacy's licence status changes continuously and must be checked at the moment of use.
What this means
- The framework governing compounding pharmacy Form 483 is cited to FDA primary sources.
- The record holding each element of facility is named.
- Verification dates are published on every field so staleness is visible.
What this does not mean
- That any entity connected with compounding pharmacy Form 483 is compliant or non-compliant.
- That the absence of a record indicates the absence of an issue.
- That this platform certifies or endorses any facility or preparation.
Status terms on this page follow the platform's published status vocabulary.
- No entity-specific record relating to compounding pharmacy Form 483 has been verified at this snapshot.
- Facility may change without notice to this platform.
- Regulatory positions change through rulemaking, guidance, and enforcement action.
- Records held by different agencies may disagree; conflicts are published as conflicts.
Sources verified for this page — 10 sources
- FDA — Information for Outsourcing Facilitieschecked 2026-07-23
- FDA — Q&A: Outsourcing Facility Registrationchecked 2026-07-23
- FDA — Registered Outsourcing Facilitieschecked 2026-07-23
- FDA — Aligning Federal and State Regulation of Compounderschecked 2026-07-23
- FDA — Outsourcing Facility Feeschecked 2026-07-23
- FDA — Compounded Drug Products That Are Essentially Copieschecked 2026-07-23
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)checked 2026-07-23
- FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)checked 2026-07-23
- Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)checked 2026-07-23
- FDA — Outsourcing Facility Fees guidancechecked 2026-07-23
Why compounding pharmacy Form 483 is hard to verify
Three structural features of compounding oversight make verification harder than it looks, and they apply to this topic as much as any other.
First, authority is split. Federal and state regulators hold different records about the same entity, and neither register is complete on its own. Second, registration and inspection are separate events — a facility can be registered for years without an inspection, so a registration date tells you nothing about oversight intensity. Third, a record's currency is invisible without its date: a licence verified last year and a licence verified today look identical in a citation.
That is why every field on this platform carries a check date, and why a field without one renders as pending rather than as a fact.
| Structural feature | Consequence for verification | How this platform handles it |
|---|---|---|
| Split federal and state authority | No single register is complete for any entity | Both systems are named per field, and neither is presented as sufficient |
| Registration precedes inspection | A registration is not evidence of oversight | Registration and inspection are reported as separate facts |
| Records go stale silently | A citation without a date implies currency it may not have | Every field carries its own verification date |
| Observations are not findings | A Form 483 is frequently reported as a violation | Observations and final actions are stored and displayed separately |
| Resolved actions persist online | Closed matters get reported as current | Current and historical status are distinct states, never merged |
Related records in this section
Section hub: Alerts and enforcement · Methodology · Status definitions · Right to respond
Frequently asked questions
What does this page cover on compounding pharmacy Form 483?
Facility; inspection; observations; response; later warning letter/classification; not-final-determination context.
What is established about facility?
Facility is tracked as part of compounding pharmacy Form 483. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What is established about inspection?
inspection is tracked as part of compounding pharmacy Form 483. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What is established about observations?
observations is tracked as part of compounding pharmacy Form 483. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What would trigger an alert on compounding pharmacy Form 483?
Only a current official action from a named agency, with its scope stated. Consumer allegations, media reports and review sentiment never generate an alert here.
Sources
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
- FDA — Registered Outsourcing Facilities
- FDA — Aligning Federal and State Regulation of Compounders
- FDA — Outsourcing Facility Fees
- FDA — Compounded Drug Products That Are Essentially Copies
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)
- FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)
- Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)
- FDA — Outsourcing Facility Fees guidance
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.